Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Quantumscape Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $220.35 (market cap $29.60B), while Quantumscape Corp trades at $6.55 (market cap $3.90B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 7.6× Quantumscape Corp's market cap. Which is the better fit depends on your goals.
| ALNY | QS | |
|---|---|---|
Market Cap | $29.60B | $3.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $18.44 |
52-Week Low | $205.48 | $4.89 |
Enterprise Value | $27.56B | $3.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
QuantumScape (QS) trades at $6.19, up 1.89% today, with a mixed technical outlook showing bullish oscillators but bearish moving averages. The company remains pre-revenue with significant losses, reporting a net income of -$435.05M in 2025 (company filing, 2025). Recent Q2 2026 earnings beat expectations but highlighted ongoing commercialization delays, with solid-state battery targets pushed to 2029 (The Motley Fool, 2026-08-11).
The stock presents high-risk speculation due to zero revenue and persistent cash burn, offset by potential long-term disruption in battery technology. Analyst sentiment is cautious with 73% hold ratings, reflecting skepticism on near-term execution. Key risks include timeline slippage, funding needs, and competitive pressure in the EV supply chain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
